LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION April 18, 2023 TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB773 by Parker (relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), Committee Report 1st House, Substituted No significant fiscal implication to the State is anticipated. It is assumed that any costs associated with the bill could be absorbed using existing resources. Local Government ImpactNo significant fiscal implication to units of local government is anticipated. Source Agencies: b > td > 503 Texas Medical Board, 529 Health and Human Services Commission, 537 State Health Services, Department of LBB Staff: b > td > JMc, NPe, ER, APA
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION
April 18, 2023
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: SB773 by Parker (relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), Committee Report 1st House, Substituted
TO: Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
FROM: Jerry McGinty, Director, Legislative Budget Board
IN RE: SB773 by Parker (relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), Committee Report 1st House, Substituted
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Honorable Lois W. Kolkhorst, Chair, Senate Committee on Health & Human Services
Jerry McGinty, Director, Legislative Budget Board
Jerry McGinty, Director, Legislative Budget Board
SB773 by Parker (relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), Committee Report 1st House, Substituted
SB773 by Parker (relating to access to certain investigational drugs, biological products, and devices used in clinical trials by patients with severe chronic diseases.), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
No significant fiscal implication to the State is anticipated.
It is assumed that any costs associated with the bill could be absorbed using existing resources.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies: b > td > 503 Texas Medical Board, 529 Health and Human Services Commission, 537 State Health Services, Department of
503 Texas Medical Board, 529 Health and Human Services Commission, 537 State Health Services, Department of
LBB Staff: b > td > JMc, NPe, ER, APA
JMc, NPe, ER, APA